The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema

H Clark, K Reid

By lowering surface tension at the air-water interface in the surfactant deficient premature lung, exogenous surfactant replacement therapy for neonatal respiratory distress syndrome has been highly successful in decreasing mortality after preterm birth. It has emerged in recent years that surfactant components not present in current surfactant formulations—particularly surfactant associated proteins A and D (SP-A and SP-D)—have additional roles in host defence distinct from the surface tension lowering effects of surfactant. SP-A and SP-D are calcium dependent carbohydrate binding proteins of the innate immune system important in the first line defence of the lung against microorganisms and in the control of lung inflammation. This review addresses the possibility that recently developed recombinant forms of SP-D could be useful therapeutically in attenuating inflammatory processes in neonatal chronic lung disease, cystic fibrosis, and emphysema.

Pulmonary surfactant is 90% lipid and 10% protein. There are four surfactant associated proteins: SP-A, SP-B, SP-C, and SP-D. The hydrophobic and lipophilic SP-B and SP-C are important for the surface tension lowering properties of surfactant, and congenital SP-B deficiency is incompatible with life.1 Artificial surfactants (for example, Exosurf, ALEC) do not contain SP-B and SP-C, but they are present in the more effective natural surfactants such as Survanta. By contrast, the water soluble surfactant proteins, SP-A and SP-D, are lost in the process of surfactant extraction from animal lungs (bovine in the case of Survanta, porcine in the case of Curosurf) so that current surfactants in clinical use do not contain SP-A or SP-D. It has emerged recently that these proteins have important functions in pulmonary host defence and the control of lung inflammation, which raises the question of whether current surfactant therapies could be improved by supplementation with these natural surfactant components. Traditionally human SP-A and SP-D have been isolated from bronchoalveolar lavage of patients with alveolar proteinosis or from amniotic fluid, but yields (especially of SP-D) are not high from these sources and the protein exists in variable states of oligomerisation.2 Proteins from these natural sources would therefore not be very suitable as pharmaceutical agents because of their non-uniformity and difficulty of isolation, but artificial generation of recombinant forms of the proteins may allow in the future for large scale production of well defined and uniform therapeutic formulations.

THE LUNG COLLECTINS, SURFACTANT PROTEINS A AND D

SP-A and SP-D are glycoprotein belonging to the collectin family of innate immune molecules, so called because they have collagenous and lectin binding domains (CRDs) (fig 1). Evidence has accumulated over the past 10–15 years that SP-A and SP-D act in the first line immune defence of the lung, by binding to pathogens and promoting their phagocytosis and killing by phagocytes.3 SP-A knock-out mice have normal lung histology, but lack of SP-A resulted, as predicted, in an increased susceptibility to pulmonary infection to bacteria and viruses.4 By contrast, murine SP-D deficiency unexpectedly led to spontaneous emphysematous change and the development of pulmonary fibrosis,5 revealing a critically important role for SP-D, in particular, in the control of lung inflammation. This short review focuses on how advances in our understanding of the complex roles played by SP-D in the lung may be relevant to the pathogenesis of a range of paediatric and adult lung disease and how the recent development of functional recombinant forms of SP-D has significantly raised the prospects of novel therapeutics using artificially generated lung collectins.

FUNCTIONS OF SP-D

First line defence against pathogens

SP-D recognises the pattern of carbohydrate structures on the surface of a wide range of bacteria, viruses, and fungi and binds to them through multiple low affinity calcium dependent interactions. Table 1 lists examples of the broad range of pathogens with which SP-D is known to interact. SP-D also binds to macrophages and neutrophils and promotes phagocytosis and killing of bound bacteria, fungi, and viruses. SP-D is chemotactic for alveolar macrophages,7

Abbreviations: BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; COPD, chronic obstructive pulmonary disease; LPS, lipopolysaccharide; MBL, mannann binding lectin; RDS, respiratory distress syndrome; SP-A, surfactant protein A; SP-D, surfactant protein D
neutrophils, and monocytes, and acts as a rapid scavenger molecule for clearance of potentially proinflammatory bacterial components such as lipopolysaccharide (LPS). These properties suggest that SP-D acts as a soluble opsonin promoting rapid removal of pathogens and other noxious agents from the airways. Consistent with this, mice lacking SP-D show an exaggerated inflammatory response after infectious challenge.

**Immune modulation**

In addition to acting rapidly in clearance of pathogens by close interaction and modulation of phagocytic cell function, SP-D is also known to modulate the function of other immune cells. In common with other components of the innate immune system, SP-D plays a role in instructing the secondary immune response after challenge with infectious or allergic agents. For example, SP-D enhances the presentation of E. coli antigens to dendritic cells, has been shown to inhibit IL-2 dependent T lymphocyte proliferation, and has an inhibitory effect on allergen induced lymphocyte proliferation and histamine release in children with asthma. Thus SP-D not only acts in first line host defence but also affects secondary immune responses.

**Control of inflammation**

Rapid removal of apoptotic cells is recognised as a centrally important mechanism for maintenance of immune homeostasis and the resolution of inflammation. As apoptosis progresses, the integrity of the plasma membrane is lost with consequent leakage of potentially toxic intracellular contents and triggering of an inflammatory response in bystander cells. We have recently reported that SP-D deficiency in the mouse leads to an accumulation of apoptotic and necrotic alveolar macrophages in the airways. Subsequent activation of healthy bystander macrophages and the resultant increased production of reactive oxygen species and matrix metalloproteinases provides a mechanism whereby SP-D deficiency per se leads to the development of emphysema. The studies reveal a critical role for SP-D in immune homeostasis and in the regulation of inflammation in the lung by controlling apoptotic cell numbers.

**Antioxidant properties**

The enhanced production of reactive oxygen species in SP-D deficient mice may be particularly damaging because it has been shown in vitro that SP-D has potent protective properties as an antioxidant. The collectins appear to directly interfere with lipid oxidation by inhibiting the formation of lipid radicals or by acting as free radical chain terminators. The loss of these protective properties would likely contribute to oxidative lung injury and contribute to chronic inflammation in SP-D deficiency. SP-D deficiency in the mouse causes aberrant alveolar development such that emphysematous change is apparent by 4–6 weeks of life. SP-D’s antioxidant properties and its importance in modulating apoptotic cell numbers in the lung suggests a protective function for SP-D in preventing abnormal alveolar remodelling after oxidative lung injury, and perhaps also a role in immune and lung developmental processes.

Table 2 lists multiple functions of surfactant protein D.

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteria</td>
<td></td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>Kuan et al., 1992**</td>
</tr>
<tr>
<td>Salmonella minnesota</td>
<td>Kuan et al., 1992**</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>Tino and Wright, 1996**</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>Ofek et al., 2001</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>Tino et al., 1996**</td>
</tr>
<tr>
<td>Viruses</td>
<td></td>
</tr>
<tr>
<td>Influenza A</td>
<td>Levine et al., 2001</td>
</tr>
<tr>
<td>Respiratory syncytial virus</td>
<td>Hickling et al., 1999</td>
</tr>
<tr>
<td>Fungi</td>
<td></td>
</tr>
<tr>
<td>Pneumocystis carinii</td>
<td>O’ Riordan et al., 1995**</td>
</tr>
<tr>
<td>Aspergillus fumigatus</td>
<td>Strong et al., 2002**</td>
</tr>
<tr>
<td>Cryptococcus neoformans</td>
<td>Schelenz et al., 1995**</td>
</tr>
</tbody>
</table>

**SP-D BASED THERAPY FOR LUNG DISEASE—GENERATION OF RECOMBINANT SP-D**

Considerable effort has been made in recent years to develop recombinant forms of human collectins to assess their efficacy in alleviating disease in models of human respiratory infection and inflammation. However, generating adequate amounts of whole length protein is problematic. The delivery of large oligomserised proteins to the lung also presents difficulties because they may be denatured by nebulisation. However, whole length surfactant protein D may be essential for the preservation of certain functions, smaller fragments of the protein do remain biologically active in vitro and in vivo. These smaller fragments are more robust in resisting denaturation by nebulisation or aerosolisation, so that administration to non-intubated patients may become feasible. We have recently been successful in generating a truncated recombinant fragment of SP-D which maintains important biological function in vivo. This fragment lacks the greater part of the collagenous region existing as a trimer of carbohydrate binding domains which can be readily expressed in E. coli in large amounts and refolded correctly into an active form. In mice 30–40% of an intranasally administered dose of the fragment reaches the lungs and ameliorates the chronic lung inflammation seen in SP-D deficiency. Treatment of SP-D deficient mice with the recombinant fragment of human SP-D reduces the excessive numbers of alveolar macrophages in the alveolar space, partially corrected the disturbance of
surfactant lipid homeostasis, and reduced macrophage activation and the number of apoptotic macrophages persisting in the airways. The SP-D recombinant fragment preferentially binds to apoptotic and necrotic cells in vitro, consistent with an opsonic role in promoting removal of dead and dying cells to limit inflammation.28

**RELEVANCE OF SP-D TO THE PATHOGENESIS OF HUMAN LUNG DISEASE**

Table 3 lists potential disease targets for SP-D based therapy.

**Neonatal chronic lung disease (CLD)**

Surfactant replacement therapy has been very successful in reducing mortality from respiratory distress syndrome (RDS), but up to 40% of infants surviving after birth at less than 28 weeks gestation develop CLD. Both synthetic (for example, ALEC, Exosurf, Ventacute) and animal extracted surfactant preparations (for example, Survanta, Curosurf) have been used to combat RDS and contain neither SP-A nor SP-D. The lungs of premature infants are known to be deficient in all surfactant components, including SP-D. Miyamura et al reported low levels of SP-D in amniotic fluid from preterm births.21 SP-D levels in tracheal lavage samples from premature infants are low, and do not correlate with gestational age, but are related to infection status (Clark et al, unpublished data). Dexamethasone induces SP-D expression in vitro,22 and in a study by Wang et al, infants receiving postnatal dexamethasone treatment showed increased levels of SP-D from days 3 to 14, improved pulmonary status, and decreased number of days on a ventilator.23 Unfortunately the numbers in this study were too small to assess any specific association of SP-D levels with the development of chronic lung disease. However, in a more recent study, Beresford and Shaw reported a specific association between low levels of SP-D and the development of CLD. Infants developing CLD by day 28 had significantly lower SP-D levels on day 2 and day 3, whereas SP-A or surfactant protein B levels did not differ significantly between these groups over the first four days.24

The role of recurrent microbial infection in exacerbating inflammation and increasing the risk of development of neonatal lung disease has been highlighted recently.25 There is also evidence from in vitro studies showing inhibition of neutrophil phagocytosis of neonatal pathogens in the presence of some surfactant preparations (for example, Survanta, Pumactant, Exosurf) that surfactant therapy might offer some protection. However, in a more recent study, Beresford and Shaw reported a specific association between low levels of SP-D and the development of CLD. Infants developing CLD by day 28 had significantly lower SP-D levels on day 2 and day 3, whereas SP-A or surfactant protein B levels did not differ significantly between these groups over the first four days.25

<table>
<thead>
<tr>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonatal chronic lung disease</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Bacterial/ viral/fungal infection</td>
</tr>
<tr>
<td>Emphysema/COPD</td>
</tr>
<tr>
<td>Asthma</td>
</tr>
</tbody>
</table>

**Cystic fibrosis**

The importance of the innate immune system in the lungs of patients with cystic fibrosis has recently come under intense scrutiny.26 Infection with *Pseudomonas aeruginosa* (especially with organisms in the *Burkholderia cepacia* complex) and with the fungus *Aspergillus fumigatus* which causes allergic responses to compound respiratory compromise, frequently heralds marked clinical deterioration. SP-D interacts with *Pseudomonas* and promotes phagocytosis and killing of spores of *Aspergillus fumigatus* in vitro.27 SP-A and SP-D levels are decreased in bronchoalveolar lavage from patients with cystic fibrosis,51 and there is increased proteolytic degradation of SP-A52 and SP-D (Dombrowsky H, Posle AD, Reid KB, Clark H, et al, unpublished). We have recently reported that administration of native full length SP-A, SP-D,53 and a recombinant truncated fragment of human SP-D54 have in vivo protective effects in murine models of allergic hypersensitivity to *Aspergillus fumigatus*. Clearance of apoptotic cells is of critical importance in the control of inflammation and is defective in cystic fibrosis.55 We have recently shown a specific role for SP-D in controlling the numbers of apoptotic inflammatory cells in the lungs, and shown that this number is reduced with partial resolution of inflammation after administration of recombinant SP-D. Thus recombinant SP-D may have a part to play in future therapeutic strategies for cystic fibrosis, by helping combat infection, by modulating allergic responses to fungal infection, and by limiting inflammation by promoting clearance of apoptotic inflammatory cells.

**Emphysema**

The single most important risk factor for the development of chronic obstructive pulmonary disease (COPD) and emphysema in adults is cigarette smoking.56 Cigarette smoke induces alveolar macrophage apoptosis in vitro57 and in vivo.58 Majo et al have recently reported that apoptosis in lung tissue samples from smokers showed a bilinear relation with the amount smoked, increasing sharply in smokers with emphysema; they concluded that apoptosis might be one of the mechanisms of lung destruction leading to the development of emphysema.59 It has recently been reported that SP-D levels are very low in bronchoalveolar lavage of smokers.60 Relative SP-D deficiency in smokers may result in increased numbers of apoptotic cells lingering in the airways and thus contribute to emphysema in this patient group. One study has described an SP-D polymorphism seen more frequently in sufferers of COPD compared to healthy controls61; of note in this respect is the observation that high serum levels of SP-A and SP-D were predictive of survival in a population of patients with idiopathic pulmonary fibrosis.62 Against this background, the findings that recombinant SP-D...
administration to SP-D deficient mice reduces apoptotic cell numbers, raises the possibility that recombinant SP-D therapy in humans could inhibit a mechanism contributing to emphysema provoked by cigarette smoking.

CONCLUSIONS
Surfactant proteins A and D have multiple functions in immune defence and regulation in the lung. Premature infants, cystic fibrosis patients, and smokers developing emphysema are known to be deficient in SP-D. It has recently become possible to generate biologically active fragments of SP-D in large amounts that could be useful therapeutically. There is a need for further investigation to assess the potential benefits of this drug in a clinical setting.

ACKNOWLEDGEMENTS
Dr Clark was 1998 Eden Fellow in Paediatrics of the Royal College of Physicians and is currently supported by a Beit Memorial Fellowship for Medical Research. The personal work cited in this review was supported by grants from the MRC, the British Lung Foundation, and the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002 Medical Futures GlaxoSmithKline Award for the Best Innovation in the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002.

Wang JY, Fadok VA

K Reid, Paediatrics, John Radcliffe Hospital, Headington, Oxford, UK

MRC Immunochemistry Unit, Department of Biochemistry, Authors’ affiliations

Medical Futures GlaxoSmithKline Award for the Best Innovation in the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002.

emphysema are known to be deficient in SP-D. It has recently become possible to generate biologically active fragments of SP-D in large amounts that could be useful therapeutically. There is a need for further investigation to assess the potential benefits of this drug in a clinical setting.

CONCLUSIONS
Surfactant proteins A and D have multiple functions in immune defence and regulation in the lung. Premature infants, cystic fibrosis patients, and smokers developing emphysema are known to be deficient in SP-D. It has recently become possible to generate biologically active fragments of SP-D in large amounts that could be useful therapeutically. There is a need for further investigation to assess the potential benefits of this drug in a clinical setting.

ACKNOWLEDGEMENTS
Dr Clark was 1998 Eden Fellow in Paediatrics of the Royal College of Physicians and is currently supported by a Beit Memorial Fellowship for Medical Research. The personal work cited in this review was supported by grants from the MRC, the British Lung Foundation, and the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002 Medical Futures GlaxoSmithKline Award for the Best Innovation in the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002.

Wang JY, Fadok VA

K Reid, Paediatrics, John Radcliffe Hospital, Headington, Oxford, UK

MRC Immunochemistry Unit, Department of Biochemistry, Authors’ affiliations

Medical Futures GlaxoSmithKline Award for the Best Innovation in the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002.

emphysema are known to be deficient in SP-D. It has recently become possible to generate biologically active fragments of SP-D in large amounts that could be useful therapeutically. There is a need for further investigation to assess the potential benefits of this drug in a clinical setting.

CONCLUSIONS
Surfactant proteins A and D have multiple functions in immune defence and regulation in the lung. Premature infants, cystic fibrosis patients, and smokers developing emphysema are known to be deficient in SP-D. It has recently become possible to generate biologically active fragments of SP-D in large amounts that could be useful therapeutically. There is a need for further investigation to assess the potential benefits of this drug in a clinical setting.

ACKNOWLEDGEMENTS
Dr Clark was 1998 Eden Fellow in Paediatrics of the Royal College of Physicians and is currently supported by a Beit Memorial Fellowship for Medical Research. The personal work cited in this review was supported by grants from the MRC, the British Lung Foundation, and the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002 Medical Futures GlaxoSmithKline Award for the Best Innovation in the Sir Halley Stewart Trust. Dr Clark is the winner of the 2002.
The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema

H Clark and K Reid

*Arch Dis Child* 2003 88: 981-984
doi: 10.1136/adc.88.11.981

Updated information and services can be found at:
[http://adc.bmj.com/content/88/11/981](http://adc.bmj.com/content/88/11/981)

These include:

**References**

This article cites 47 articles, 22 of which you can access for free at:
[http://adc.bmj.com/content/88/11/981#BIBL](http://adc.bmj.com/content/88/11/981#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Immunology (including allergy) (2018)
- Child health (3922)
- Cystic fibrosis (182)
- Pancreas and biliary tract (269)
- Epidemiologic studies (1818)
- Pneumonia (infectious disease) (220)
- Pneumonia (respiratory medicine) (201)
- Pregnancy (528)
- TB and other respiratory infections (643)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)